Systemic Targeting of Lymph Node Metastasis through the Blood Vascular System by Using Size-Controlled Nanocarriers
Citations Over TimeTop 10% of 2015 papers
Abstract
Occult nodal metastases increase the risk of cancer recurrence, demoting prognosis and quality of life of patients. While targeted drug delivery by using systemically administered nanocarriers can potentially control metastatic disease, lymph node metastases have been mainly dealt by locally injecting nanocarriers, which may not always be applicable. Herein, we demonstrated that sub-50 nm polymeric micelles incorporating platinum anticancer drugs could target lymph node metastases in a syngeneic melanoma model after systemic injection, even after removing the primary tumors, limiting the growth of the metastases. By comparing these micelles with clinically used doxorubicin-loaded liposomes (Doxil) having 80 nm, as well as a 70 nm version of the micelles, we found that the targeting efficiency of the nanocarriers against lymph node metastases was associated with their size-regulated abilities to extravasate from the blood vasculature in metastases and to penetrate within the metastatic mass. These findings indicate the potential of sub-50 nm polymeric micelles for developing effective conservative treatments against lymph node metastasis capable of reducing relapse and improving survival.
Related Papers
- → Design and Fabrication of Magnetically Responsive Nanocarriers for Drug Delivery(2016)83 cited
- → Engineered Nanocarriers of Doxorubicin: A Current Update(2008)92 cited
- → Ligand decorated biodegradable nanomedicine in the treatment of cancer(2021)31 cited
- → An effective polymeric nanocarrier that allows for active targeting and selective drug delivery in cell coculture systems(2021)10 cited
- → Targeted Drug Delivery(2018)3 cited